Supplementary table 2: Baseline characteristics of female NIAD-users and matched female non-NIAD-users

|  |  |  |  |
| --- | --- | --- | --- |
|  | **NIAD-users** |  | **Non-NIAD-users** |
| **Characteristics** | **N=111,878** |  | **N=111,878** |
| Mean follow-up time (years, SD) | 4.4 ± 2.9 |  | 4.5 ± 2.8 |
|  |  |  |  |
| Age |  |  |  |
| Mean age at index date (years, SD) | 59.9 ± 17.3  |  | 59.9 ± 17.3 |
| 18-49 years | 29,413 (26.3%) |  | 29,413 (26.3%) |
| 50-59 years | 19,841 (17.7%) |  | 19,841 (17.7%) |
| 60-69 years | 25,396 (22.7%) |  | 25,396 (22.7%) |
| 70+ years | 37,228 (33.3%) |  | 37,228 (33.3%) |
|  |  |  |  |
| BMI |  |  |  |
| Mean BMI at index date (kg/m2, SD) | 32.0 ± 7.4 |  | 26.5 ± 5.6 |
| <24.9 kg/m2 | 16,862 (15.1%) |  | 45,333 (40.5%) |
| 25.0-29.9 kg/m2 | 29,604 (26.5%) |  | 33,140 (29.6%) |
| 30.0-34.9 kg/m2 | 28,530 (25.5%) |  | 15,054 (13.5%) |
| ≥35.0 kg/m2 | 32,612 (29.1%) |  | 7,855 (7.0%) |
| Missing | 4,270 (3.8%) |  | 10,496 (9.4%) |
|  |  |  |  |
| HbA1c |  |  |  |
| <6.0 % | 1,259 (1.1%) |  | 770 (0.7%) |
| 6.0-6.9 % | 5,070 (4.5%) |  | 513 (0.5%) |
| 7.0-7.9 % | 8,584 (7.7%) |  | 54 (0.0%) |
| 8.0-8.9 % | 4,816 (4.3%) |  | 6 (0.0%) |
| ≥9.0 % | 7,004 (6.3%) |  | 2 (0.0%) |
| Missing  | 85,145 (76.1%) |  | 110,533 (98.8%) |
|  |  |  |  |
| eGFR |  |  |  |
| ≥90 mL/min/1.73m² | 15,727 (14.1%) |  | 5,592 (5.0%) |
| 60-89 mL/min/1.73m² | 40,030 (35.8%) |  | 21,812 (19.5%) |
| 30-59 mL/min/1.73m²  | 19,464 (17.4%) |  | 10,722 (9.6%) |
|  45-59 mL/min/1.73m²  | 14,363 (12.8%) |  | 8,081 (7.2%) |
|  30-45 mL/min/1.73m²  | 4,448 (4.0%) |  | 2,108 (1.9%) |
| 15-29 mL/min/1.73m²  | 786 (0.7%) |  | 334 (0.3%) |
| <15 mL/min/1.73m²  | 97 (0.1%) |  | 44 (0.0%) |
| Missing | 35,774 (32.0%) |  | 73,374 (65.6%) |
|  |  |  |  |
| Smoking status  |  |  |  |
| Never | 66,685 (59.6%) |  | 68,211 (61.0%) |
| Current | 20,424 (18.3%) |  | 21,391 (19.1%) |
| Ex | 23,841 (21.3%) |  | 20,247 (18.1%) |
| Missing  | 928 (0.8%) |  | 2,029 (1.8%) |
|  |  |  |  |
| Alcohol use |  |  |  |
| No | 41,910 (37.5%) |  | 26,877 (24.1%) |
| Yes | 61,664 (55.1%) |  | 72,882 (65.1%) |
| Missing  | 8,304 (7.4%) |  | 12,119 (10.8%) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **NIAD-users** |  | **Non-NIAD-users** |
| **Characteristics** | **N=111,878** |  | **N=111,878** |
| History of diseases |  |  |  |
| Hypertension | 44,388 (39.7%) |  | 24,960 (22.3%) |
| Renal failure acute | 296 (0.3%) |  | 102 (0.1%) |
| Renal failure chronic | 803 (0.7%) |  | 361 (0.3%) |
| Renal failure total | 1,061 (0.9%) |  | 449 (0.4%) |
| Postmenopausal status | 18,704 (16.7%) |  | 21,242 (19.0%) |
| Oophorectomy | 5,129 (4.6%) |  | 4,243 (3.8%) |
|  |  |  |  |
| Drug use six months before index date |  |  |  |
| Thiazide diuretics | 22,066 (19.7%) |  | 16,104 (14.4%) |
| Loop diuretics | 12,721 (11.4%) |  | 6,272 (5.6%) |
| Low dose aspirin | 47 (0.0%) |  | 16 (0.0%) |
| Statins | 44,373 (39.7%) |  | 15,500 (13.9%) |
| Ciclosporine | 53 (0.0%) |  | 44 (0.0%) |
| Tacrolimus | 88 (0.1%) |  | 50 (0.0%) |
|  |  |  |  |
| Diabetes medication 6 months before index date |  |  |  |
| Metformin | 27,160 (24.3%) |  | n/a |
| Sulfonylureaderivatives | 3,935 (3.5%) |  | n/a |
| Thiazolidinediones | 16,466 (14.7%) |  | n/a |
| Insulin  | 9,317 (8.3%) |  | n/a |
| Incretins | 249 (0.2%) |  | n/a |
| Meglitinides | 341 (0.3%) |  | n/a |